Guj. Themis Bio.

Why is Gujarat Themis Biosyn Ltd falling/rising?

As of 30-Jun, Gujarat Themis Biosyn Ltd's stock price is rising to Rs 396.80, reflecting a 3.27% increase after a trend reversal. Despite a year-to-date decline, the stock shows strong long-term performance and bullish indicators, although a significant drop in investor participation suggests caution.

As of 30-Jun, Gujarat Themis Biosyn Ltd's stock price is rising, currently at Rs 396.80, reflecting an increase of Rs 12.55 or 3.27%. This upward movement follows a trend reversal after two consecutive days of decline. The stock has outperformed its sector by 2.68% today and reached an intraday high of Rs 400.5, indicating positive momentum. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a strong bullish trend.<BR><BR>Despite a year-to-date decline of 10.32%, the stock has shown significant long-term performance, with a 14.55% increase over the past year and an impressive 278.74% rise over the last three years. The company's high management efficiency, evidenced by a return on equity (ROE) of 29.26% and a low debt to EBITDA ratio of 2.14 times, further supports its stability and growth potential. However, it is important to note that there has been a significant drop in investor participation, with delivery volume falling by 87.29% against the 5-day average, which could indicate caution among investors. Overall, the current rise in stock price is attributed to a combination of positive performance metrics and a reversal from recent declines.

Which are the latest news on Guj. Themis Bio.?

Should I buy, sell or hold Gujarat Themis Biosyn Ltd?

How big is Guj. Themis Bio.?

As of 10th June, Gujarat Themis Biosyn Ltd has a market capitalization of 4,299.00 Cr, with recent net sales of 165.82 Cr and a net profit of 46.67 Cr. Shareholder's funds are valued at 248.38 Cr, and total assets amount to 301.31 Cr.

As of 10th June, Gujarat Themis Biosyn Ltd has a market capitalization of 4,299.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 165.82 Cr and a Net Profit of 46.67 Cr.<BR><BR>For the latest annual period ending March 2025, the Shareholder's Funds were valued at 248.38 Cr, while the Total Assets amounted to 301.31 Cr.

Who are in the management team of Guj. Themis Bio.?

The management team of Guj. Themis Bio includes Chairman Dinesh S Patel, Non-Executive Director Sachin D Patel, and five Independent Non-Executive Directors: Vijay Gopi Kishan Agarwal, Kirandeep Madan, Vikram D Sanghvi, and Siddharth Y Kusumgar.

The management team of Guj. Themis Bio includes the following members:<BR><BR>1. **Dinesh S Patel** - Chairman & Non-Executive Director<BR>2. **Sachin D Patel** - Non-Executive Director<BR>3. **Vijay Gopi Kishan Agarwal** - Independent Non-Executive Director<BR>4. **Kirandeep Madan** - Independent Non-Executive Director<BR>5. **Vikram D Sanghvi** - Independent Non-Executive Director<BR>6. **Siddharth Y Kusumgar** - Independent Non-Executive Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Guj. Themis Bio.?

Peers of Guj. Themis Bio. include FDC, Aarti Pharma, Senores Pharma, Innova Captab, Bliss GVS Pharma, Orchid Pharma, Advanced Enzyme, IOL Chemicals, Gufic BioScience, and Zota Health Care. Senores Pharma shows excellent growth and management risk, while Guj. Themis Bio. has a 1-year return of 9.86%, higher than Aarti Pharma's -31.67% but lower than Senores Pharma's 117.66%.

Peers: The peers of Guj. Themis Bio. are FDC, Aarti Pharma, Senores Pharma., Innova Captab, Bliss GVS Pharma, Orchid Pharma, Advanced Enzyme, IOL Chemicals, Gufic BioScience, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Senores Pharma., Innova Captab, and Guj. Themis Bio., while Average management risk is found at FDC, Aarti Pharma, Bliss GVS Pharma, Advanced Enzyme, IOL Chemicals, Gufic BioScience, and the rest. Below Average management risk is noted at Orchid Pharma. Growth is Excellent at Senores Pharma., while Below Average growth is seen at FDC, Aarti Pharma, Innova Captab, Bliss GVS Pharma, Advanced Enzyme, IOL Chemicals, Gufic BioScience, Guj. Themis Bio., and the rest. Orchid Pharma has Below Average growth as well. Capital Structure is Excellent at FDC, Aarti Pharma, Innova Captab, Bliss GVS Pharma, Guj. Themis Bio., Advanced Enzyme, and IOL Chemicals, while Good is noted at Senores Pharma., and Average at Gufic BioScience and Zota Health Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma. at 117.66%, while the lowest is Aarti Pharma at -31.67%. Guj. Themis Bio. has a 1-year return of 9.86%, which is significantly higher than Aarti Pharma but lower than Senores Pharma. Additionally, Gufic BioScience and Zota Health Care have negative six-month returns.

What does Guj. Themis Bio. do?

Gujarat Themis Biosyn Ltd is a small-cap pharmaceutical and biotechnology company, incorporated in 1981 and currently owned by the Yuhan Group. As of March 2026, it reported net sales of ₹44 Cr and a net profit of ₹11 Cr, with a market cap of ₹4,299 Cr.

Overview:<BR>Gujarat Themis Biosyn Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was incorporated in 1981 and underwent a significant change in ownership in June 1991 when it was taken over by the Yuhan Group from South Korea and a consortium of Indian pharmaceutical companies. The latest reported quarter for sales and profit is March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 44 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 11 Cr (Quarterly Results - Mar 2026) <BR>Market cap: INR 4,299 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 90.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.17% <BR>Debt Equity: 0.54 <BR>Return on Equity: 16.22% <BR>Price to Book: 15.03 <BR><BR>Contact Details:<BR>Address: 69/C GIDC Industrial Estate, Valsad Dist VAPI Gujarat : 396195 <BR>Tel: 91-260-2430027 <BR>Email: accounts@gtbl.co.in/gtblmumbai@gtbl <BR>Website: http://www.gtbl.in

Are Gujarat Themis Biosyn Ltd latest results good or bad?

Gujarat Themis Biosyn Ltd's latest Q4 FY26 results are concerning, showing a 17.20% revenue growth but a 9.25% decline in net profit and significant margin compression. Overall, the decline in profitability raises doubts about the sustainability of their growth.

Gujarat Themis Biosyn Ltd's latest results for Q4 FY26 indicate a challenging performance. While the company achieved a revenue growth of 17.20% year-on-year, net profit fell by 9.25% compared to the same quarter last year, and even more significantly, by 12.60% from the previous quarter. This decline in profitability is concerning, especially given the sharp contraction in operating profit margin, which decreased to 43.77% from 49.14% in the prior quarter.<BR><BR>Despite the top-line growth, the deterioration in margins suggests that the company is facing significant operational challenges. The PAT margin also compressed, indicating that the profitability pressure is not just a one-off issue. Overall, while the revenue growth is a positive sign, the decline in net profit and margins raises red flags about the sustainability of this growth and the company's ability to maintain its premium valuation in the market.<BR><BR>In summary, the latest results can be considered bad, primarily due to the significant margin compression and profit decline, overshadowing the revenue growth.

When is the next results date for Gujarat Themis Biosyn Ltd?

The next results date for Gujarat Themis Biosyn Ltd is 25 May 2026.

The next results date for Gujarat Themis Biosyn Ltd is scheduled for 25 May 2026.

Is Guj. Themis Bio. technically bullish or bearish?

As of November 20, 2025, the trend is mildly bullish due to positive weekly MACD and KST signals, though caution is warranted from a mildly bearish weekly Dow Theory and lack of momentum in the RSI.

As of 20 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the weekly MACD and KST indicators showing bullish signals, while the daily moving averages also indicate a mildly bullish trend. However, the weekly Dow Theory is mildly bearish, which adds some caution. The RSI shows no signal on both weekly and monthly timeframes, suggesting a lack of momentum. Overall, the strength of the bullish stance is tempered by mixed signals from other indicators.

How has been the historical performance of Guj. Themis Bio.?

Guj. Themis Bio. experienced fluctuating net sales, reporting 150.80 Cr in Mar'25, down from 169.82 Cr in Mar'24 but up from 148.39 Cr in Mar'23. Profit metrics also declined, with profit after tax at 48.77 Cr in Mar'25, while total assets rose significantly to 301.31 Cr.

Answer:<BR>The historical performance of Guj. Themis Bio. shows a fluctuating trend in net sales and profitability over the years, with a notable increase in total operating income and profit margins in recent years.<BR><BR>Breakdown:<BR>Guj. Themis Bio. reported net sales of 150.80 Cr in Mar'25, a decrease from 169.82 Cr in Mar'24, but an increase from 148.39 Cr in Mar'23. The total operating income followed a similar pattern, peaking at 169.82 Cr in Mar'24 before declining to 150.80 Cr in Mar'25. The company's operating profit (PBDIT) was 71.27 Cr in Mar'25, down from 83.11 Cr in Mar'24, while profit before tax also decreased to 65.54 Cr from 79.33 Cr. Profit after tax for Mar'25 was reported at 48.77 Cr, a decline from 59.16 Cr in the previous year. The operating profit margin (excluding other income) was 45.65% in Mar'25, slightly down from 46.37% in Mar'24. Total assets increased significantly to 301.31 Cr in Mar'25 from 221.11 Cr in Mar'24, driven by a rise in total reserves to 237.49 Cr. The company also saw an increase in long-term borrowings to 29.64 Cr in Mar'25, compared to none in the previous year. Cash flow from operating activities improved to 91.00 Cr in Mar'25, up from 64.00 Cr in Mar'24, contributing to a net cash inflow of 5.00 Cr in Mar'25.

Who are the top shareholders of the Guj. Themis Bio.?

The top shareholders of Guj. Themis Bio include Pharmaceutical Business Group [India] Ltd with 47.02%, individual investors holding 19.31%, and foreign institutional investors at 2.51%. Additionally, mutual funds hold 1.16%, with Quant Mutual Fund - Quant Manufacturing Fund being the largest public shareholder at 1.15%.

The top shareholders of Guj. Themis Bio include the promoters, with the Pharmaceutical Business Group [India] Ltd holding the largest stake at 47.02%. Additionally, there are mutual funds involved, with five schemes collectively holding 1.16%, and foreign institutional investors (FIIs) holding 2.51% through ten different entities. The highest public shareholder is Quant Mutual Fund - Quant Manufacturing Fund, which has a holding of 1.15%. Individual investors also have a significant presence, owning 19.31% of the company.

Is Guj. Themis Bio. overvalued or undervalued?

As of May 5, 2021, Guj. Themis Bio. is considered very expensive and overvalued with a PE Ratio of 72.45 and an EV to EBITDA of 51.24, significantly higher than competitors like Sun Pharma and Cipla, despite its impressive returns over the past three years.

As of 5 May 2021, the valuation grade for Guj. Themis Bio. moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently deemed overvalued. Key ratios include a PE Ratio of 72.45, an EV to EBITDA of 51.24, and a Price to Book Value of 15.82, all of which are substantially higher than industry peers. <BR><BR>In comparison, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE Ratio of 22.99 and an EV to EBITDA of 15.93, highlighting that Guj. Themis Bio. is trading at a premium relative to these competitors. Additionally, despite its high returns over various periods, including a 511.99% return over three years compared to the Sensex's 49.20%, the elevated valuation metrics suggest that the stock may not be justified at its current price level.

What is the bonus history of the Guj. Themis Bio.?

Gujarat Themis Biosyn Ltd announced a 1:2 bonus issue, with an ex-date of August 9, 2024, meaning shareholders will receive 1 additional share for every 2 shares held.

Gujarat Themis Biosyn Ltd has a recent bonus issue history where they announced a 1:2 bonus. The ex-date for this bonus is set for August 9, 2024. This means that for every 2 shares held, shareholders will receive 1 additional share. If you need further details or have more questions about the company, feel free to ask!

Has Guj. Themis Bio. declared dividend?

Gujarat Themis Biosyn Ltd has declared a 25% dividend, amounting to ₹0.25 per share, with an ex-date of July 15, 2024. The company has shown strong total returns over various periods, particularly impressive over the long term, despite recent fluctuations.

Gujarat Themis Biosyn Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 0.25<BR>- Ex-date: 15 Jul 24<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.51%, the dividend return was 0%, resulting in a total return of -4.51%.<BR><BR>Over the past year, the price return was 24.43%, the dividend return was 0.09%, leading to a total return of 24.52%.<BR><BR>In the two-year period, the price return was 215.74%, the dividend return was 1.90%, culminating in a total return of 217.64%.<BR><BR>For the three-year period, the price return was 477.99%, the dividend return was 19.37%, resulting in a total return of 497.36%.<BR><BR>In the four-year span, the price return was 768.42%, the dividend return was 36.29%, which led to a total return of 804.71%.<BR><BR>Over the last five years, the price return was 1327.87%, the dividend return was 64.80%, resulting in a total return of 1392.67%.<BR><BR>Overall, Gujarat Themis Biosyn Ltd has declared a dividend while also showing significant total returns over various periods, particularly impressive over the longer term, indicating strong performance despite recent fluctuations.